8-K: Bionano Genomics Completes $18 Million Private Placement, Retires Existing Debt

Bionano Genomics has finalized a private placement of senior secured convertible debentures, raising $18 million to retire existing debt and improve its financial flexibility.

Summary

• Bionano Genomics has completed a private placement of senior secured convertible debentures due in 2026, raising $18 million in gross proceeds.
• The funds will be used to fully retire the company's existing convertible debt from October 2023, which was amended in February 2024.
• The new financing aims to strengthen Bionano's capital structure, improve liquidity, and support the adoption of optical genome mapping.
• The debentures have a maturity date of May 24, 2026, and an interest rate of 11% per annum, payable monthly.
• The company may redeem the debentures at any time, subject to certain equity conditions, by paying the outstanding principal, accrued interest, and a redemption premium of 112% if redeemed before the first anniversary or 106% if redeemed after.
• Holders of the debentures can require the company to redeem up to $1 million per month starting July 24, 2024.
• The debentures are convertible into common stock at a price of $2.00 per share, subject to adjustments for stock splits and dividends.
• The company is restricted from incurring additional debt, granting liens, repurchasing securities, paying dividends, or selling assets outside the ordinary course of business while the debentures are outstanding.
• The company must maintain a cash balance equal to the lesser of $11 million or the outstanding principal balance of the debentures in a blocked account.

Sentiment

Score: 4

Explanation: While the company has successfully raised capital and addressed near-term debt, the document highlights significant risks and uncertainties about its future viability, leading to a negative sentiment.

Positives

• The private placement provides significant financial flexibility by retiring near-term debt maturities.
• The new financing defers principal redemption payments, reducing near-term cash needs.
• The transaction strengthens the company's capital structure and improves its liquidity position.
• The company can continue to drive adoption and utilization of optical genome mapping.
• The company is reviewing strategic alternatives to maximize shareholder value.

Negatives

• The company is subject to restrictions on incurring debt, granting liens, and other financial activities while the debentures are outstanding.
• The company must maintain a minimum cash balance in a blocked account.
• The company's available cash, cash-equivalents and short-term investments following consummation of the transaction will not be sufficient to achieve cash-flow break even.
• The company has determined that there is substantial doubt about its ability to continue as a going concern within 12 months of the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.

Risks

• The company may not be able to continue as a going concern without additional financing.
• The company may have to reorganize or liquidate its business if it cannot raise sufficient additional capital.
• Investors may lose all or part of their investment if the company is unable to continue as a going concern.
• The company's available cash, cash-equivalents and short-term investments following consummation of the transaction will not be sufficient to achieve cash-flow break even.

Future Outlook

The company believes the net proceeds from the offering and restructuring of redemption terms, together with existing cash, will be sufficient to fund operating expenses and capital expenditure requirements into at least the fourth quarter of 2024. The company will continue to seek to raise additional capital, but without additional financing the company may not be able to continue as a going concern. The Board has established a strategy committee to work with the Company and outside advisors in evaluating the Companys options and considering alternatives that it believes will maximize stakeholder value.

Management Comments

• This new financing reinforces the strategic plan set out by the Company in February 2024, by strengthening its capital structure, improving its liquidity position, and enhancing the Companys ability to continue to drive adoption and utilization of optical genome mapping while it continues to review strategic alternatives to maximize shareholder value.

Industry Context

This announcement reflects a trend of biotech companies seeking private financing to address immediate debt obligations and improve their financial positions. The focus on strategic alternatives also indicates a broader industry trend of companies exploring various options to maximize shareholder value in a challenging market environment.

Comparison to Industry Standards

• The terms of the convertible debentures, including the interest rate and conversion price, are within the range of similar financings in the biotech sector.
• The redemption premium is relatively standard for convertible debt instruments.
• The restrictions on the company's financial activities are typical for companies with outstanding debt obligations.
• The requirement to maintain a minimum cash balance is a common covenant in debt agreements.

Stakeholder Impact

• Shareholders face the risk of losing all or part of their investment if the company cannot continue as a going concern.
• Employees may be impacted by potential reorganizations or liquidations.
• Customers may experience disruptions if the company's financial situation deteriorates.
• Creditors may face increased risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company will file a Current Report on Form 8-K with the SEC detailing the private placement and debenture terms.
• The company will continue to seek additional capital to fund future operations.
• The company's strategy committee will evaluate options and consider alternatives to maximize stakeholder value.

Key Dates

Keywords

private placement, convertible debentures, debt restructuring, optical genome mapping, capital structure, liquidity, senior secured notes, financial flexibility, redemption premium, conversion price